Platelet/vessel wall interactions, rheologic factors and thrombogenic substrate in acute coronary syndromes:

P C Adams1, V Fuster, L Badimon

  • 1Mount Sinai School of Medicine, City University of New York, New York 10029.

Insights

Thrombosis, or blood clot formation, is central to acute coronary syndromes. Understanding plaque fissuring and platelet interactions is key to developing new preventive strategies for heart attacks and related conditions.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pathophysiology

Background:

  • Thrombosis is a critical factor in acute coronary syndromes (ACS), including myocardial infarction and unstable angina.
  • Atherosclerotic plaque fissuring initiates the thrombotic process in ACS.
  • Platelet activation, aggregation, and rheologic factors significantly influence thrombus formation at sites of vascular injury.

Purpose of the Study:

  • To elucidate the pathogenetic mechanisms of thrombosis in acute coronary syndromes.
  • To explore the role of plaque fissuring, platelet dynamics, and rheologic factors in ACS development.
  • To identify potential targets for preventive strategies against ACS.

Main Methods:

  • Review of the pathogenetic sequence in unstable angina, from plaque fissuring to intermittent ischemia.
  • Analysis of factors influencing platelet adhesion and aggregation.
  • Consideration of rheologic factors, stenosis, and shear rates in thrombus formation.
  • Discussion of current and potential therapeutic interventions.

Main Results:

  • Plaque fissuring is a key event, leading to platelet activation and thrombus formation.
  • The severity of vessel wall injury and rheologic factors determine the extent of thrombosis.
  • Unstable angina involves labile thrombosis and intermittent ischemia, potentially exacerbated by vasoconstriction.
  • Myocardial infarction may result from more extensive damage and permanent thrombus formation.

Conclusions:

  • Targeting platelet inhibition and employing peptide receptor blockers or monoclonal antibodies are promising preventive strategies.
  • Management of rheologic factors through stenosis prevention, angioplasty, or thrombolytic therapy is crucial.
  • Further research into the role of thrombosis in ACS will advance primary prevention efforts.

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...